A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors
Memorial Sloan Kettering Cancer Center
Summary
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Documentation of Disease: * Patients must have pathologic confirmation of one of three diseases: * Diffuse pleural mesothelioma (DPM) * Gastroesophageal carcinoma (GEC) including adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach. * PD-L1 CPS ≥1 (using clone 73-10, DAKO) * HER2 overexpression negative (using clone 4B5, Ventana): HER2 IHC 0-1+, or HER2 2+ with ISH showing HER2:CEP17 ratio \<2 and average HER2 copy number \<6.0 signals/cell * Urothelial carcinoma (UC) * Archival tissue is acceptable * Metastatic or advanced/un…
Interventions
- DrugBMS-986504
BMS-986504 PO daily
- DrugIpilimumab
Ipilimumab (1mg/kg Q6wk)
- DrugNivolumab
Nivolumab (360mg flat dose Q3wk)
- Drug5-FU
are continued until disease progression or intolerance
- DrugLeucovorin
are continued until disease progression or intolerance
- DrugOxaliplatin
are continued until disease progression or intolerance
- DrugGemcitabine
Gemcitabine are given for a maximum of 6 cycles
Locations (7)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York